Tirzepatide is a weekly injection that activates GIP and GLP-1 receptors, sold by Eli Lilly as Zepbound and Mounjaro.
Quick answers for Miami
- Weight loss without diabetes: Zepbound, $299 to $449 a month cash through LillyDirect [1].
- Type 2 diabetes: Mounjaro, often through insurance; list price $1,112.16 per 28 days [3]. With commercial coverage, Lilly's card can bring it to $25 [5].
- Florida Medicaid: no GLP-1 coverage for obesity [4].
- Medicare: the GLP-1 Bridge covers the Zepbound KwikPen, not vials, for $50 a month if you qualify [6].
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in Miami, from $300 a month.
Sponsored placements are labeled and bought by local practices. We do not endorse them.
Miami-Dade's diabetes rate and the two labels
CDC's 2023 numbers for Miami-Dade put diagnosed diabetes at 15.4% of adults against obesity at 29.5% [2], a high diabetes share for that obesity level. For those adults, Mounjaro's label covers blood sugar control in type 2 diabetes plus lowering major heart-event risk in high-risk patients [7]. Zepbound's label covers weight management and, in adults with obesity, moderate to severe obstructive sleep apnea [8]. Prescribing Mounjaro purely for weight is off-label. Compare them in Mounjaro vs Zepbound.
Zepbound price by dose
| Dose | Monthly price | If refill is late | Source |
|---|---|---|---|
| 2.5 mg | $299 | Same | [1] |
| 5 mg | $399 | Same | [1] |
| 7.5 mg | $449 | $499 | [1] |
| 10, 12.5, 15 mg | $449 | $699 | [1] |
Lilly cut these vial prices on December 1, 2025, from $349, $499 and $499 [9]. Track changes on tirzepatide cost and Zepbound cost.
Trial results, stated as averages
At the 15 mg dose in SURMOUNT-1, adults without diabetes lost an average of 20.9% of body weight over 72 weeks; at 5 mg the average was 15.0%, and on placebo 3.1% [10]. In SURMOUNT-4, after a 36-week lead-in, people switched to placebo regained an average of 14.0% of body weight over the next year, while those who stayed on tirzepatide lost another 5.5% [11]. More at tirzepatide results.
Cheaper compounded offers in South Florida
FDA's March 2025 end to enforcement discretion for 503A tirzepatide compounding followed its finding that the shortage was over [12]. What remains legal is a one-patient prescription where the prescriber writes down a significant difference for that person [12]. These products are unapproved, and FDA reviews none of them for safety, effectiveness or quality [13]. UHealth, the University of Miami system, runs a bariatric surgery program; its page does not confirm medical weight management [[16]]. More: compounded tirzepatide.
From the Zepbound label
Do not use tirzepatide if you or a family member has had medullary thyroid carcinoma or MEN 2. Stop and call your prescriber for severe stomach pain that will not go away, which may be pancreatitis, or for swelling, rash or trouble breathing. Low blood sugar risk rises with insulin or a sulfonylurea. Stop Zepbound when pregnancy is recognized [14]. Call 911 in an emergency.
Elsewhere in Florida
Compare tirzepatide in Boca Raton, Orlando and Tampa, or read where to get tirzepatide near you. The tirzepatide guide covers the basics, and tirzepatide online lists telehealth options. Check prescribers with the Florida Board of Medicine [15].
Questions people ask
What is the cash price of Zepbound in Miami?
Through LillyDirect it runs $299 to $449 a month depending on strength, checked October 17, 2026 [1].
With type 2 diabetes and job-based insurance, what might Mounjaro cost me?
Can a Miami Medicare enrollee get Zepbound for $50?
Yes, if eligible: the Medicare GLP-1 Bridge covers the Zepbound KwikPen at $50 a month through December 31, 2027, but not vials [6].
What share of Miami-Dade adults have diabetes?
CDC PLACES estimates 15.4% of Miami-Dade County adults had diagnosed diabetes in 2023 [2].
Does Florida Medicaid cover Zepbound for obesity?
No. Florida Medicaid does not cover GLP-1s for obesity, per KFF's January 2026 review [4].
Who licenses Miami doctors who prescribe tirzepatide?
The Florida Board of Medicine, part of the Florida Department of Health, licenses physicians and offers a license lookup [15].
What happened when people stopped tirzepatide in SURMOUNT-4?
After 36 weeks on the drug, those switched to placebo regained an average of 14.0% of body weight by week 88, while those who continued lost another 5.5% [11].
Sources
16 cited
- Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
- PLACES county estimates: Miami-Dade County, FL. CDC PLACES (2025 release, BRFSS 2023), 2025 release.
- Mounjaro FAQ. Eli Lilly and Company, accessed 2026-10-17.
- Medicaid coverage of and spending on GLP-1s. KFF, Jan 16, 2026.
- Mounjaro savings card terms. Eli Lilly and Company, accessed 2026-10-17.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
- Mounjaro label. DailyMed, NLM, Aug 2026.
- Zepbound label. DailyMed, NLM, Aug 2026.
- Lilly lowers Zepbound vial prices on LillyDirect. Eli Lilly and Company, Dec 1, 2025.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine (PubMed), Jun 4, 2022.
- Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA (PubMed), Jan 1, 2024.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, Apr 1, 2026.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
- Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration, Apr 2026.
- Florida Board of Medicine. Florida Department of Health, accessed 2026-10-17.
- UHealth Bariatrics (weight loss surgery). University of Miami Health System, accessed 2026-10-17.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.